| 2413- | TTT, | Tumor treating fields (TTFields) impairs aberrant glycolysis in glioblastoma as evaluated by [18F]DASA-23, a non-invasive probe of pyruvate kinase M2 (PKM2) expression |
| - | in-vitro, | GBM, | U87MG |
| 2412- | TTT, | A review of tumor treating fields (TTFields): advancements in clinical applications and mechanistic insights |
| - | Review, | GBM, | NA |
| 3747- | TTT, | Tumor treating induced fields: a new treatment option for patients with glioblastoma |
| - | in-vitro, | GBM, | U87MG |
| 6456- | TUR, | Ar-turmerone inhibits the proliferation and mobility of glioma by downregulating cathepsin B |
| - | in-vitro, | GBM, | U251 | - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | LN229 |
| 6452- | TUR, | Turmeric Essential Oil Constituents as Potential Drug Candidates: A Comprehensive Overview of Their Individual Bioactivities |
| - | Review, | Nor, | NA |
| 6453- | TUR, | Pharmacological Profile, Bioactivities, and Safety of Turmeric Oil |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 6454- | TUR, | Selective induction of apoptosis by ar-turmerone isolated from turmeric (Curcuma longa L) in two human leukemia cell lines, but not in human stomach cancer cell line |
| - | in-vitro, | AML, | HL-60 | - | in-vitro, | GC, | NA |
| 6460- | TUR, | CUR, | Neuroprotective Effect of Turmeric Extract in Combination with Its Essential Oil and Enhanced Brain Bioavailability in an Animal Model |
| - | in-vivo, | AD, | NA |
| 6459- | TUR, | Curcumin combined with turmerones, essential oil components of turmeric, abolishes inflammation-associated mouse colon carcinogenesis |
| - | in-vivo, | Nor, | NA | - | in-vivo, | Colon, | NA |
| - | in-vitro, | lymphoma, | U937 |
| 6457- | TUR, | The Role of Turmerones on Curcumin Transportation and P-Glycoprotein Activities in Intestinal Caco-2 Cells |
| - | in-vitro, | Colon, | Caco-2 |
| 6455- | TUR, | Induction of apoptosis by ar-turmerone on various cell lines |
| - | in-vitro, | AML, | K562 | - | in-vitro, | lymphoma, | U937 |
| 5904- | TV, | Pharmacological Properties and Molecular Mechanisms of Thymol: Prospects for Its Therapeutic Potential and Pharmaceutical Development |
| - | Review, | Var, | NA | - | Review, | Stroke, | NA | - | Review, | Diabetic, | NA | - | Review, | Obesity, | NA | - | Review, | AD, | NA | - | Review, | Arthritis, | NA |
| 5934- | TV, | Protective Effects of Natural Antioxidants on Inflammatory Bowel Disease: Thymol and Its Pharmacological Properties |
| - | Review, | Var, | NA |
| 5911- | TV, | Thymol Isolated from Thymus vulgaris L. Inhibits Colorectal Cancer Cell Growth and Metastasis by Suppressing the Wnt/β-Catenin Pathway |
| - | vitro+vivo, | CRC, | NA |
| 5935- | TV, | CAR, | Effects of thymol and carvacrol supplementation on intestinal integrity and immune responses of broiler chickens challenged with Clostridium perfringens |
| - | in-vivo, | Nor, | NA |
| 2350- | UA, | Ursolic acid-mediated changes in glycolytic pathway promote cytotoxic autophagy and apoptosis in phenotypically different breast cancer cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 2411- | UA, | Ursolic acid in health and disease |
| - | Review, | Var, | NA |
| 3790- | UA, | Therapeutic applications of ursolic acid: a comprehensive review and utilization of predictive tools |
| 3789- | UA, | Ex, | Combined Ursolic Acid and Resistance/Endurance Training Improve Type 3 Diabetes Biomarkers-Related Memory Deficits in Hippocampus of Aged Male Wistar Rats |
| - | in-vivo, | AD, | NA |
| 3788- | UA, | RosA, | Ursolic acid and rosmarinic acid ameliorate alterations in hippocampal neurogenesis and social memory induced by amyloid beta in mouse model of Alzheimer’s disease |
| - | in-vivo, | AD, | NA |
| 5017- | UA, | Ursolic acid disturbs ROS homeostasis and regulates survival-associated gene expression to induce apoptosis in intestinal cancer cells |
| - | in-vitro, | Cerv, | INT-407 | - | in-vitro, | CRC, | HCT116 |
| 5018- | UA, | Ursolic acid in cancer prevention and treatment: Molecular targets, pharmacokinetics and clinical studies |
| - | Review, | Var, | NA |
| 5019- | UA, | Ursolic acid in colorectal cancer: mechanisms, current status, challenges, and future research directions |
| - | Review, | Var, | NA |
| 5020- | UA, | Anticancer activity of ursolic acid on human ovarian cancer cells via ROS and MMP mediated apoptosis, cell cycle arrest and downregulation of PI3K/AKT pathway |
| - | in-vitro, | Ovarian, | NA |
| 5021- | UA, | Anticancer effect of ursolic acid via mitochondria-dependent pathways |
| - | Review, | Var, | NA |
| 5022- | UA, | Ursolic Acid’s Alluring Journey: One Triterpenoid vs. Cancer Hallmarks |
| - | Review, | Var, | NA |
| 5023- | UA, | CA, | RosA, | Therapeutic Effect of Rosemary and Its Active Constituent on Nervous System Disorders |
| - | Review, | Park, | NA | - | Review, | AD, | NA |
| 1139- | UA, | Ursolic acid inhibits epithelial-mesenchymal transition by suppressing the expression of astrocyte-elevated gene-1 in human nonsmall cell lung cancer A549 cells |
| - | in-vitro, | Lung, | A549 |
| 1058- | UA, | Ursolic acid, an antagonist for transforming growth factor (TGF)-beta1 |
| - | in-vivo, | NA, | NA |
| 1020- | UA, | Root Bark of Morus alba L. and Its Bioactive Ingredient, Ursolic Acid, Suppress the Proliferation of Multiple Myeloma Cells by Inhibiting Wnt/β-Catenin Pathway |
| - | in-vitro, | Melanoma, | RPMI-8226 |
| 119- | UA, | CUR, | RES, | Combinatorial treatment with natural compounds in prostate cancer inhibits prostate tumor growth and leads to key modulations of cancer cell metabolism |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 942- | UA, | Ursolic Acid Inhibits Breast Cancer Metastasis by Suppressing Glycolytic Metabolism via Activating SP1/Caveolin-1 Signaling |
| - | vitro+vivo, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 1310- | UA, | Ursolic acid triggers apoptosis and Bcl-2 downregulation in MCF-7 breast cancer cells |
| - | in-vitro, | BC, | MCF-7 |
| 4869- | Uro, | Urolithin A in Central Nervous System Disorders: Therapeutic Applications and Challenges |
| - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | Stroke, | NA |
| 4859- | Uro, | Rad, | Urolithin A Enhances Tight Junction Protein Expression in Endothelial Cells Cultured In Vitro via Pink1-Parkin-Mediated Mitophagy in Irradiated Astrocytes |
| - | in-vitro, | Nor, | NA |
| 4868- | Uro, | Urolithin A improves Alzheimer’s disease cognition and restores mitophagy and lysosomal functions |
| - | in-vivo, | AD, | NA |
| 4867- | Uro, | Urolithin A exhibits a neuroprotective effect against Alzheimer’s disease by inhibiting DYRK1A activity |
| - | in-vivo, | AD, | NA | - | in-vitro, | AD, | HEK293 |
| 4865- | Uro, | Urolithin A suppresses high glucose-induced neuronal amyloidogenesis by modulating TGM2-dependent ER-mitochondria contacts and calcium homeostasis |
| - | in-vitro, | Diabetic, | NA | - | in-vitro, | AD, | NA |
| 4864- | Uro, | Therapeutic Potential of Mitophagy-Inducing Microflora Metabolite, Urolithin A for Alzheimer's Disease |
| - | Review, | AD, | NA |
| 4863- | Uro, | Urolithin A reduces amyloid-beta load and improves cognitive deficits uncorrelated with plaque burden in a mouse model of Alzheimer's disease |
| - | in-vivo, | AD, | NA |
| 4862- | Uro, | Neuroprotective effect of Urolithin A via downregulating VDAC1-mediated autophagy in Alzheimer's disease |
| - | in-vivo, | AD, | NA | - | in-vitro, | Nor, | PC12 |
| 4861- | Uro, | Urolithin A improves Alzheimer's disease cognition and restores mitophagy and lysosomal functions |
| - | in-vivo, | AD, | NA |
| 4860- | Uro, | Urolithins–gut Microbial Metabolites with Potential Health Benefits |
| - | Review, | Nor, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 4857- | Uro, | Evaluation and comparison of the anti-proliferative and anti-metastatic effects of urolithin A and urolithin B against esophageal cancer cells: an in vitro and in silico study |
| - | in-vitro, | ESCC, | KYSE-30 |
| 4870- | Uro, | Urolithin A attenuates memory impairment and neuroinflammation in APP/PS1 mice |
| - | in-vivo, | AD, | NA |
| 4871- | Uro, | DHA, | LT, | A Synergistic Combination of DHA, Luteolin, and Urolithin A Against Alzheimer’s Disease |
| - | in-vitro, | AD, | NA |
| 4872- | Uro, | Urolithin A exhibits a neuroprotective effect against Alzheimer's disease by inhibiting DYRK1A activity |
| - | in-vitro, | AD, | HEK293 |
| 4873- | Uro, | Urolithin A Inhibits Anterior Basolateral Amygdala to Ventral Hippocampal CA1 Circuit to Ameliorate Amyloid-β-Impaired Social Ability |
| - | in-vivo, | AD, | NA |
| 4874- | Uro, | EGCG, | A Combination Therapy of Urolithin A+EGCG Has Stronger Protective Effects than Single Drug Urolithin A in a Humanized Amyloid Beta Knockin Mice for Late-Onset Alzheimer's Disease |
| - | in-vivo, | AD, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid